← Leaderboards
Maria Constance Athanasiou
Marpam Pharma, Llc
$2,721,153
Attributed
$5,442,305
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,442,305 · 5
By mechanism
R42$4,481,557 · 2
R41$960,748 · 3
Top collaborators
- Pamela J Skinner10 shared
- Daniel Schmidt1 shared
Others in their field
Other Emerging Leaders on “Viral”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$160,855,334
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,911,178
- John Damon Chodera · Sloan-Kettering Inst Can Research$51,025,260
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- Thomas Denny · Duke University$37,546,967
Research focus
ViralBlr1 GeneVirusCd8-Positive T-LymphocytesB-LymphocytesVirus ReplicationHomingMacaca MulattaDisease RemissionT-LymphocyteCellsAutologousImmuneChimeric Antigen Receptor T CellsChimeric Antigen ReceptorIn VivoHiv-1Pilot ProjectsLymphoid TissueCar T Cell TherapySitePhenotypeAntiretroviral TherapyPre-Clinical
Grant awards (11)
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$979,050
R42 · FY2025 · AI · contact PI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$1,000,449
R42 · FY2024 · AI · contact PI
Proof of concept studies for in vivo produced CAR-T cells that target B cell follicles as a treatment for HIV$302,248
R41 · FY2024 · AI · contact PI
Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells$306,500
R41 · FY2023 · AI · contact PI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$118,524
R42 · FY2023 · AI · contact PI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$55,000
R42 · FY2023 · AI · contact PI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$1,009,537
R42 · FY2022 · AI · contact PI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$300,000
R42 · FY2022 · AI · contact PI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$1,018,997
R42 · FY2021 · AI · contact PI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$52,000
R41 · FY2021 · AI · contact PI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$300,000
R41 · FY2020 · AI · contact PI